The antibody is specific to FLT4.
Vascular endothelial growth factor is a key regulator of blood vessel development in embryos and angiogenesis in adult tissues. Unlike VEGF, the related VEGFC stimulates the growth of lymphatic vessels through its specificl ymphatic endothelial receptor VEGFR-3. In 1998, Dumont showed that targeted inactivation of the VEGFR-3 gene in mice resulted in defective blood vessel development in early embryos. Vasculogenesis and angiogenesis occurred, but large vessels became abnormally organized with defective lumens, leading to fluid accumulation in the pericardial cavity and cardiovascular failure at embryonic day 9.5. Thus, VEGFR3 has an essential role in the development of theembryonic cardiovascular system before the emergence of the lymphatic vessels.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: chylous ascites; FLT 4; FLT-4; FLT4; FLT41; Fms like tyrosine kinase 4; fms related tyrosine kinase 4; Fms-like tyrosine kinase 4; fms-related tyrosine kinase 4; LMPH1A; PCL; receptor protein tyrosine kinase; Tyrosine-protein kinase receptor FLT4; Vascular endothelial growth factor receptor 3; vascular endothelial growth factor receptor-3; VEGFR 3; VEGFR-3; VEGFR3
Gene Aliases: AI323512; Chy; FLT-4; FLT4; FLT41; LMPH1A; PCL; VEGFR-3; VEGFR3